Kanagawa, Japan

Pohsing Ng


 

Average Co-Inventor Count = 8.0

ph-index = 2

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2013-2015

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Pohsing Ng: Innovator in Cancer Therapy

Introduction

Pohsing Ng is a notable inventor based in Kanagawa, Japan. He has made significant contributions to the field of cancer therapy through his innovative work on anti-CDH3 antibodies. With a total of 2 patents, his inventions are paving the way for advancements in targeted cancer treatments.

Latest Patents

Ng's latest patents focus on anti-CDH3 antibodies and their applications in cancer therapy. The first patent describes anti-CDH3 antibodies that can be labeled with a radioisotope. This invention provides methods and pharmaceutical compositions that include an anti-CDH3 antibody as an active ingredient. Given that CDH3 is strongly expressed in various cancer cells, including pancreatic, lung, colon, prostate, breast, gastric, and liver cancers, this invention holds promise for effective therapies in these areas. The second patent reiterates the same focus on anti-CDH3 antibodies labeled with a radioisotope, emphasizing their utility in cancer treatments.

Career Highlights

Pohsing Ng is currently associated with Oncotherapy Science, Incorporated, where he continues to develop innovative solutions for cancer treatment. His work is characterized by a commitment to improving patient outcomes through targeted therapies.

Collaborations

Ng collaborates with esteemed colleagues such as Hiroki Yoshioka and Yasuhiro Shiba, contributing to a dynamic research environment focused on advancing cancer therapies.

Conclusion

Pohsing Ng's contributions to the field of cancer therapy through his patents on anti-CDH3 antibodies highlight his role as an influential inventor. His work not only showcases innovation but also offers hope for improved cancer treatments in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…